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ABSTRACT
THE RAS EFFECTOR NORE1A FORMS A TUMOR SUPPRESSOR COMPLEX
WITH BRCA1
Nicholas C. Nelson
October 9th, 2015
Ras proteins function as molecular signaling switches that can stimulate multiple
mitogenic pathways in response to extracellular signaling. Oncogenic activation of Ras
by structural mutation is a highly transforming event in ~1/3 of human cancers. However,
aberrant Ras activation can also promote oncogene-induced senescence. This Rasinduced irreversible growth arrest is a physiological process that acts as a barrier to
malignancy. The mechanisms by which Ras drives senescence and how this process is
bypassed during Ras-driven transformation remains poorly understood.
Although mutations in the RAS gene are extremely rare in human breast cancer,
the Ras signaling pathway is constitutively activated in roughly half of all primary breast
tumors. This is largely due to aberrant activation of upstream regulators of Ras, like the
EGFR family member Her2 and inactivation of negative Ras regulators, such as NF1.
NORE1A (RASSF5) is a direct Ras effector that acts as a tumor suppressor by
promoting apoptosis and senescence. Expression of NORE1A is frequently lost in
primary breast tumors and breast cancer cell lines, though its mechanism of action in
breast cancer pathogenesis remains unclear.
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BRCA1 is a tumor suppressor that plays a key role in DNA DSB repair. Loss of BRCA1
is associated with hereditary breast and ovarian cancer, and is also thought to play a role
in sporadic breast cancer. Recently, BRCA1 was shown to play a role in both Her2 and
Ras senescence, but the mechanism underlying the communication between Her2/Ras
and BRCA1 was not identified.
I have discovered that NORE1A forms an endogenous, Her2/Ras-regulated
complex with BRCA1. I show that dual suppression of NORE1A and BRCA1 has a
synergistic effect on transformation. Furthermore, I show that NORE1A loss suppresses
the BRCA1-mediated senescence effect. Finally, I show that NORE1A and BRCA1
synergize to modulate DNA repair. Thus, I identify a novel tumor suppressor complex
that connects Her2/Ras senescence signaling to BRCA1 in breast cancer.
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CHAPTER I: INTRODUCTION TO RAS

Ras history
Nearly two decades of research on the Harvey and Kirsten murine sarcoma
retroviruses led to the discovery in the late 1970s and early 1980s that the sequences
responsible for the transforming capabilities of these viral strains were actually derived
from rat cellular genes, termed Ras (from rat sarcoma) [1]. The subsequent discovery of
mutationally activated Ras genes in human cancer cells showed that Ras could play a role
in human tumorigenesis [1], [2]. Intensive research into the structural, biochemical, and
biological functions of Ras over the last thirty years has revealed much about how Ras
communicates with both its upstream activators and downstream targets. However, the
identification of multiple Ras regulators and effectors with unique expression patterns
and intercellular functions has complicated the search for Ras-specific anti-cancer
therapies [2], [3].
Structure and regulation of Ras
There are three human RAS genes (H-RAS, N-RAS, and K-RAS) that encode
four homologous 21kDa proteins (K-RAS encodes two splice variants), all of which
associate with cellular membranes. Ras is a guanosine nucleotide-binding protein
(specifically, a small GTPase) that can bind and hydrolyze guanosine triphosphate (GTP)
into guanosine diphosphate (GDP). When bound to GTP, Ras is “switched on” and can
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bind and activate multiple signaling pathways [4]. After GTP hydrolysis, Ras undergoes a
conformational change that “turns off” Ras signaling. Ras is normally present in this
inactive (GDP-bound) conformation (Figure 1) [3].
The process of exchanging bound GDP for GTP is facilitated by Ras GEFs
(guanine nucleotide exchange factors). In response to external stimuli (e.g. mitogens,
cytokines, and growth factors), Ras GEFs are recruited to Ras proteins where they
catalyze a reaction that releases GDP from Ras [5]. Intracellular GTP is highly abundant
compared to GDP, and preferentially enters the nucleotide binding region of Ras [6].
These GTP-bound Ras proteins undergo a conformational change that allows them to
bind and activate effectors that carry information from the cell membrane to various
intracellular signaling networks [4]. Ras has a weak intrinsic GTPase activity that can
theoretically allow it to hydrolyze GTP and return to its inactive state in response to
cellular feedback. This slow, inefficient process is greatly accelerated by Ras GAPs
(GTPase activating proteins) that bind and stabilize the catalytic machinery of Ras and
thereby enhance its hydrolytic activity [7]. It is therefore the balance between Ras GEF
and GAP activity that regulates Ras signaling to its downstream effectors.
In a normal cell, Ras acts as a binary signaling switch that cycles between an
inactive (GDP-bound) state and an active (GTP-bound) state [8]. The most common
oncogenic mutations of Ras prevent stimulation of GTP hydrolysis by Ras GAPs,
resulting in permanently GTP-bound (i.e. constitutively active) Ras proteins that
continuously signal to downstream pathways [9]. These activating mutations in Ras are
present in ~1/3 of all human cancers, making Ras the most common oncogene in human
cancer [10].

2

In addition to mutations in the Ras gene itself, genetic alterations in Ras
regulatory elements can also lead to constitutive Ras signaling (Figure 2). Mutation or
amplification of the epidermal growth factor receptor Her2, which is upstream of Ras and
signals through Ras, accounts for ~25-30% of wild-type Ras activation in human breast
cancer [11]–[13]. Genetic, epigenetic, or proteasomal inactivation of the Ras GAPs NF1,
DAB2IP, and RASAL2 also account for significant wild-type Ras activation in human
breast cancer [14]–[16]. Therefore, Ras is potentially constitutively activated in over 2/3
of all human cancers (and nearly half of all breast cancers), making Ras and its
downstream pathways extremely important targets in cancer research.
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Figure 1: The Ras activation/deactivation cycle is regulated by GEFs and GAPs
Ras cycles between an active (GTP-bound) state and an inactive (GDP-bound state) due
to regulation by its guanosine nucleotide exchange factors (GEFs) and GTPase-activating
proteins (GAPs). GEFs release GDP from Ras, allowing Ras to preferentially bind to
abundant intracellular GTP. Activated Ras is then able to stimulate its target effectors.
GAPs stabilize the catalytic machinery of Ras, enhancing its intrinsic ability to hydrolyze
GTP into GDP and returning Ras to its inactive conformation.
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Figure 2: Wild-type Ras is constitutively activated by mutations in its regulatory
elements.
Oncogenic Ras mutations occur in less than 2% of breast cancers, yet Ras is
constitutively activated in over half of all primary breast tumors. This is a result of
aberrant activation of upstream regulators of Ras that signal through Ras (such as Her2)
or inactivation of negative regulators of Ras (such as the Ras GAPs NF1, DAB2IP, and
RASAL2).

5

Ras signaling overview
Mitogenic signaling
Activated Ras proteins promote transformation by stimulating multiple mitogenic
pathways (Figure 3) [17]. Constitutive activation of Ras simultaneously drives cellular
proliferation and suppresses apoptosis via these signaling pathways by enhancing
transcription of growth factors and anti-apoptotic molecules and down-regulating proapoptotic mediators [18], [19]. Two of the best-studied pathways that are activated by
Ras are the RAF-MEK-MAPK pathway and the PI3K-AKT pathway [17].
In response to signaling from cell surface receptors (e.g. EGFR receptors), the
Ras GEF Sos facilitates Ras activation, stimulating activated Ras to bind and promotes
the phosphorylation and activation of RAF, which phosphorylates and activates MEK,
which phosphorylates and activates ERK (MAPK). Activation of this signaling cascade
ultimately activates the ETS family of transcription factors that induce expression of
multiple genes that enhance cell cycle progression and migration [20]. The frequency of
aberrant Ras-RAF pathway activation in human cancer has driven intense research into
the development of RAF inhibitors for the treatment of these cancers [21], [22].
The P13K pathway is the second best characterized of the Ras effector pathways.
Upon activation by Ras, PI3K stimulates the activation of AKT, which phosphorylates
and activates numerous cellular proteins that lead to both the inhibition of multiple tumor
suppressors (e.g. p53, p27, TSC1/2) and activation of multiple oncogenes [23].
Activation of the PI3K-AKT pathway ultimately results in cell growth and survival, cell
cycle progression, migration, and cytoskeletal reorganization [24]. Similar to RAF, PI3K
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mutations are frequent in human cancers, and intense research has been focused on the
development of specific inhibitors of this pathway [23], [25].
Ras can also bind and activate RalGDS, a guanine nucleotide exchange factor
(GEF) for the small GTPase Ral. The interaction between Ras and RalGDS brings
RalGDS into proximity with Ral. Activated Ral interacts with a variety of proteins,
through which it regulates endocytosis, exocytosis, microtubule reorganization, and
transcription [26]. Activation of these pathways ultimately enhances Ras-mediated
transformation by promoting anchorage-independent cell growth [26].

Apoptosis
Activated Ras is highly transforming, yet in normal cells excessive Ras activation
can induce a powerful pro-apoptotic response (Figure 4) [27], [28]. This is usually
mediated through p53, and acts to protect cells from transformation in the presence of
oncogenic stimuli [28]. Signaling through the Ras effector RASSF1A can lead to
apoptosis via activation of caspase 3 and the pro-apoptotic proteins BAX and BAK1 or
via phosphorylation of MST kinases and activation of the pro-apoptotic Hippo pathway
[9]. In some cases, oncogenic Ras signaling through the RAF pathway can initiate a p53mediated apoptotic response [29]. The paradoxical mechanism by which Ras signaling
can both induce and abrogate apoptosis by RAF activation remains to be fully
understood, as the outcome varies greatly depending on cell/tissue type and cellular
context, as well as signal intensity and duration [28].

Senescence
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In addition to activating pro-apoptotic pathways, activated Ras can also promote
oncogene-induced senescence [28], [30]. This physiological process has been observed in
cell culture systems and in vivo mouse models as well as human rasopathies and
premalignant human tumors [30]–[33], and has been hypothesized to protect cells that
acquire Ras mutations from cancer development by stimulating them to undergo
irreversible growth arrest [34]. While the mechanism behind Ras-driven senescence
remains poorly understood, activation of the p53-p21 and p16-Rb pathways by Ras has
been shown to play an important role [35]. Importantly, abrogation of p53-p21 or p16-Rb
signaling allows cells to bypass Ras-induced senescence [30]. The RASSF family
member NORE1A is known to play a key role in Ras senescence signaling via p53 [36]
(Figure 4).
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Figure 3: Ras activates mitogenic pathways.
Oncogenic Ras mutations lock Ras in its GTP-bound (active) state, resulting in
constitutive Ras signaling. Mutation or overexpression of Ras regulatory elements can
also lead to constitutive activation of wild-type Ras. The Raf pathway ultimately
activates the ETS family of transcription factors, which stimulate the transcription of
genes that promote cell cycle progression. Activation of PI3K-AKT leads to the
phosphorylation and inhibition of several tumor suppressors (p27, p53, TSC1/2, BAD) or
activation of oncogenes. Ras can also activate the small GTPases RalA and RalB via
RalGDS, which promote anchorage-independent growth. PLCε catalyzes the formation of
IP3 and DAG, second messengers involved in intracellular calcium release and activation
of protein kinase C (PKC). RIN1 facilitates Ras-regulated endocytosis by acting as a GEF
for proteins involved in endosome maturation.
Figure copied with permission from [17] (Nature Publishing Group, license no. 3693130867077).

9

10

Figure 4: Activated Ras also stimulates growth inhibitory pathways.
In addition to mitogenic signaling, activated Ras can also drive apoptosis and senescence.
Ras signaling through Raf can promote p53-mediated apoptosis, and has also been
implicated in senescence induction via p21 and p16. Ras-mediated activation of
RASSF1A leads to apoptosis via activation of pro-apoptotic BAX proteins, or by
activation of the pro-apoptotic Hippo pathway via phosphorylation of the MST kinases.
RASSF1A has also been reported to drive senescence via p53-independent regulation of
p21. Ras-mediated activation of NORE1A can promote p53-dependent upregulation of
p21 to drive cell cycle arrest or senescence.
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Ras growth inhibitory effectors
The RASSF family
There are ten RASSF family members (along with various isoforms), which are
now split into two groups: the “classical” members (RASSF1-6), which contain an RA
domain and a SARAH domain at their C-terminus, and the N-terminal members
(RASSF7-10) that lack a SARAH domain and contain an RA domain at their N-terminus
[37]. Most of these proteins act as tumor suppressors in the cell and have been implicated
in a variety of cellular mechanisms, including apoptosis, senescence, cell cycle
regulation, and microtubule stabilization [38]. The best studied of the RASSF proteins are
RASSF1A and NORE1A [39].
NORE1A (RASSF5) can regulate Ras signaling to p53 [36], [40], and thus
directly links Ras to this senescence pathway [41]. Epigenetic inactivation of NORE1A
and other RASSF family members is a frequent occurrence in primary human tumors, as
their loss allows cells to subvert Ras-mediated cell death and promotes transformation
[38].
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CHAPTER II: RAS SIGNALING IN BREAST CANCER

Breast cancer overview
Breast cancer is the most common invasive cancer in women worldwide [42], and
can be classified as either hereditary or sporadic. Inherited mutations in certain high
penetrance genes (such as BRCA1, BRCA2, or p53) promote breast cancer formation if
the second allele of these genes becomes inactivated [43]. The majority of breast cancers
are sporadic, and arise from the stepwise accumulation of acquired mutations [44]. The
mutational activation of oncogenes (like Her2) and inactivation of tumor suppressors
leads to genomic instability via this pathway, facilitating the accumulation of additional
mutations that can promote tumor formation. Thus, both hereditary and sporadic breast
cancers are genetic diseases, and are associated with the loss or mutation of multiple
regulatory genes that control proliferation, apoptosis, and differentiation [44].

Ras activation in breast cancer
The high incidence of activating Ras mutations in various cancers (e.g. 90% of
pancreatic cancers, 50% of colon cancers, 30% of lung cancers) supports the idea that
aberrant Ras activation is a driving force in the development and advancement of these
malignancies [10]. The use of in vitro knockdown studies [45] and transgenic mouse
models [46], [47] further confirmed this idea that mutant Ras is highly transforming.
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However, less than 2% of all primary breast tumors contain activating Ras mutations
[48]–[50]. This observation has led to the widely held belief that Ras is unimportant for
breast cancer. Yet despite the low frequency of mutations, considerable experimental
evidence exists to support an important role for aberrant Ras activation and signaling in
human breast tumorigenesis [11], [51], [52]. Rather than direct mutational activation, Ras
appears to be oncogenically activated in breast cancer by mutation or altered expression
of its upstream activators (transmembrane growth factor receptors such as EGFRs) or
negative regulators (GAPs) (Figure 2).

Ras GAPs
As mentioned in Chapter I, Ras cycles between an activated state (regulated by
GEFs) and an inactivated state (regulated by GAPs). Ras GAPs are negative regulators of
Ras that enhance its intrinsic GTPase activity. Loss or mutation of these GAPs renders
Ras unable to return to its inactive state, resulting in constitutive Ras signaling. Several
loss of function mutations have been discovered in the Ras GAP RASAL2, and RASAL2
is suppressed or lost in ~20% of primary breast tumors and ~33% of breast cancer cell
lines [14]. Additionally, the Ras GAP DAB2IP was found to be reduced by promoter
hypermethylation in ~49% of primary breast tumors and ~48% of breast cancer cell lines
[15]. Spontaneous loss of the Ras GAP NF1 has been shown to occur in ~28% of all
human breast cancers [16], and is also associated with an autosomal dominant disorder
that predisposes patients to breast cancer [53].

Her2/Neu
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Human epidermal growth factor receptor 2 (Her2/Neu) is a member of the
epidermal growth factor receptor (EGFR) family that lies upstream of Ras and signals
through Ras [54]. In normal cells, Her2 becomes activated by ligand binding and
transiently activates Ras, causing Ras to activate multiple downstream effectors that
promote proliferation and survival [52]. Her2 mutation or amplification occurs in ~2530% of all breast cancers [11][12][13], resulting in hyper-activation of Her2 and thus
constitutive activation of wild-type Ras. This sustained Her2/Ras activation has been
linked to the development and progression of invasive breast carcinomas [51].
Her2 activation is an early event in human breast tumorigenesis, and Her2positive cancers usually have a worse prognosis and an increased propensity for brain
metastasis compared to non-Her2 cancers [55][56][57]. Paradoxically, activation of Her2
can also promote oncogene-induced senescence [58], [59]. The molecular mechanisms
underlying Her2-induced senescence and how it is bypassed during transformation are
complex and remain poorly understood. One factor that clearly plays a key role is
activation of the Ras pathway [60].

Her2/Ras activation promotes incomplete senescence in immortalized cells
Both Her2 and Ras overexpression have been reported to drive senescence in
primary human mammary epithelial cells (HMECs) [58][61]. However, although
oncogenic Her2 or Ras expression in MCF-10A immortalized, non-transformed human
mammary epithelial cells results in the phenotype of senescence (senescence-associated
morphological changes, enhanced β-galactosidase activity, upregulation of p21) it fails to
trigger irreversible growth arrest [62]. These cells are able to stably persist in state of
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incomplete senescence, and can be driven toward full senescence (growth arrest) or
transformation by enhanced genotoxic stress or loss of critical cell cycle regulators [62].

NORE1A and BRCA1 link activated Ras signaling to breast cancer
Two tumor suppressor proteins that have been shown to play roles in both cell
cycle regulation via p53-p21 [40], [63] and senescence via activated Ras [36], [64] are
the RASSF family member NORE1A and the breast cancer susceptibility protein
BRCA1. NORE1A is a direct Ras effector, and is inactivated in ~40% of breast cancer
cell lines and primary tumors by promoter hypermethylation [65]. BRCA1 expression is
frequently lost in sporadic breast cancers by promoter hypermethylation [66]–[69], and
mutational inactivation of BRCA1 is linked to a hereditary breast and ovarian cancer
(HBOC) syndrome [43]. The frequency of co-inactivation of these tumor suppressors in
breast cancer is not known. The similar roles of these proteins in activation of the CDK
inhibitor p21, a marker of senescence induction, coupled with their recently identified
roles in Ras senescence suggests that these proteins may be acting to protect cells from
breast tumor formation by regulating senescence induction after Ras activation.
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CHAPTER III: THE NORE1A TUMOR SUPPRESSOR

NORE1A overview
NORE1A structure
Nore1/RASSF5 was the first member of the RASSF family to be characterized
[70]. There are three known isoforms of NORE1 as a result of alternative splicing,
RASSF5A (NORE1A), RASSF5B, and RASSF5C (NORE1B) [38]. NORE1A is the fulllength (418aa; 47kDa) protein, and the most widely expressed. It consists of an Nterminal proline-rich region that contains a nuclear localization sequence, followed by a
cysteine-rich domain (CRD) that serves as a putative diacylglycerol/phorbol ester
(DAG/PE)-binding site, a Ras association (RA) domain for binding Ras, and a C-terminal
SARAH domain where it binds the pro-apoptotic MST kinases (Figure 5). The
intermediate domain (INT) between the CRD and RA domains contains a second nuclear
localization sequence, and the RA domain contains a nuclear export sequence [71].

Subcellular localization
NORE1A is a nucleocytoplasmic shuttling protein, and contains two identified
nuclear localization signals and one identified nuclear export signal (Figure 5). NORE1A
has been reported on microtubules and in the centrosome [72], but can most readily be
detected in the nucleus. Phosphorylation of NORE1A by the tyrosine kinase Lck
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regulates its nuclear translocation via an importin-mediated pathway [73]. This nuclear
translocation of NORE1A is critical for its role in cell cycle regulation [73]. Nuclear
export of NORE1A was shown to be required for NORE1A-mediated apoptosis induction
[74], and likely occurs via a CRM1-mediated pathway [73], [74]. Thus, the subcellular
localization of NORE1A plays an important role in its tumor suppressor function.

Regulation and inactivation in human cancer
NORE1A is reported to be regulated by phosphorylation by Lck [73] and Aurora
kinase [75], and can also be poly-ubiquitinated by the E3 ubiquitin ligase Itch in a
manner dependent on the level of NORE1A acetylation [76]. This ubiquitination results
in NORE1A degradation by the 26S proteasome; thus, Itch acts a negative regulator of
NORE1A [76]. The precise mechanism by which NORE1A is acetylated and marked for
degradation remains unknown [76].
Another way in which NORE1A expression is regulated is by hypermethylation
of its promoter region [77]. NORE1A is expressed in a wide variety of normal tissues,
and is frequently downregulated by promoter hypermethylation in several cancer cell
lines and primary tumors, including liver, lung, breast, and kidney cancers [65], [78].

Hippo signaling/apoptosis
NORE1A lacks enzymatic activity, and therefore likely functions as a scaffolding
protein. The best-studied functions of NORE1A are its ability to bind specifically and
with high specificity to Ras and the proapoptotic kinase MST1, a component of the
Hippo pathway (Figure 6). The Hippo pathway controls organ size in mammals by
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regulating the balance between cell proliferation and apoptosis [79]. Earlier studies
implicated Ras/NORE1A in the regulation of apoptosis via MST1 [80]. However, more
recent research shows that while NORE1A and MST1 can form an endogenous complex
in human cells, the kinase activity of MST1 is strongly suppressed in these complexes
[81]. Additionally, deletion studies show that the ability of NORE1A to bind MST is not
critical for its growth suppressive function [81]. Thus, canonical Hippo signaling via
MST1 does not appear to be a major tumor suppressor function of NORE1A.

Cell cycle regulation and senescence
Although earlier studies identified a pro-apoptotic role for NORE1A [80], [82],
recent research suggests that a more physiological role for NORE1A may be in the
regulation of cell cycle arrest by p53 [40]. In support of this, NORE1A was shown to be a
critical component of Ras-driven senescence signaling to p53 [36] (Figure 6). Senescence
induced by Ras acts as a barrier to transformation in cells that have acquired constitutive
activation of Ras [34]. In the absence of NORE1A, Ras becomes uncoupled from p53 and
is able to drive transformation without the barrier of senescence [36]. Thus, the
communication link between Ras, p53, and NORE1A is critical for the tumor suppressor
function of NORE1A.
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Figure 5: NORE1A protein structure.
Full-length NORE1A contains a proline-rich region at its N-terminus that contains a
nuclear localization signal (aa 51-100), followed by a cysteine-rich domain (CRD; also
referred to as a zinc-finger) that functions as a DAG/PE binding domain. The C-terminal
end of NORE1A contains a Ras association (RA) domain where it binds to activated Ras,
and a coiled-coil SARAH domain required for binding the MST kinases. I refer to the
~100aa region between the CRD and RA domains as the intermediate (INT) domain. This
INT domain is reported to contain a second nuclear localization sequence (aa 200-260).
Finally, a nuclear export sequence has been reported between aa 260-300.
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Figure 6: NORE1A signaling pathways
NORE1A can bind directly to activated Ras and the proapoptotic MST kinases, which
form the start of the Hippo signaling pathway. MST activation leads to phosphorylation
of LATS kinases via the Salvador (SAV) adaptor protein, and ultimately the
phosphorylation and inactivation of transcriptional co-activators YAP and TAZ. The role
of NORE1A in Hippo signaling is controversial and remains poorly understood.
NORE1A can also communicate with p53 to induce senescence in the presence of
activated Ras. Recently, NORE1A was shown to scaffold the ubiquitin ligase β-TrCP
with its target substrate β-catenin in a Ras-dependent manner, which marks β-catenin for
degradation by the 26S proteasome [83].
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NORE1A in human cancer
NORE1A is frequently downregulated in human tumors and tumor cell lines by
promoter hypermethylation [65], and loss of heterozygosity (LOH) at the NORE1A locus
has been observed in primary tumors [84]. Furthermore, a translocation involving
NORE1A is associated with a hereditary human cancer syndrome [85]. Overexpression
of NORE1A can promote apoptosis [80], [82], cell cycle arrest [81], or senescence [36],
and restoration of endogenous NORE1A levels to a human tumor cell line that is negative
for NORE1A suppresses the tumorigenic phenotype [82]. Additionally, mouse embryonic
fibroblasts (MEFs) from NORE1A-/- mice can be transformed by activated Ras without
the presence of additional oncogenes, where wild-type MEFs are not susceptible to this
one-step transformation [86]. Subcutaneous injection of activated Ras-expressing MEFs
or NORE1A-/- MEFs into nude mice did not promote significant tumor formation after 35 weeks. However, Ras+/NORE1A-/- MEFs formed tumors in these mice in 3 weeks [86].
Thus, the evidence supports a role for NORE1A as a tumor suppressor and Ras effector
that acts as a barrier to protect cells from Ras-driven transformation.
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CHAPTER IV: THE BRCA1 TUMOR SUPPRESSOR

BRCA1 overview
The breast cancer type 1 susceptibility gene (BRCA1) is a tumor suppressor that
functions to maintain genomic integrity, largely by participating in DNA repair.
Hereditary mutations in BRCA1 strongly predispose carriers to developing breast and
ovarian cancers [87]. BRCA1 inactivation by promoter hypermethylation has also been
observed in a considerable proportion of sporadic breast cancers [88]. Thus, loss or
dysregulation of BRCA1 function is a frequent occurrence in all types of breast cancers.

BRCA1 structure/function
BRCA1 encodes a 1,863 AA (~220 kDa) protein (Figure 7) that plays an
important role in maintaining genomic stability by forming protein complexes with DNA
repair proteins and other tumor suppressors in order to carry out its diverse roles in DNA
repair, cell cycle control, transcriptional regulation, apoptosis, and centrosome
duplication (Figure 8) [89]. BRCA1 is able to simultaneously participate in several
different protein complexes, as each complex contains only a small fraction of the total
cellular BRCA1 [90].
Three domains of BRCA1 are responsible for the majority of its biological
functions and protein interactions: an N-terminal RING (Really Interesting New Gene)
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domain, a central domain encoded by exons 11-13, and two tandem BRCT (BRCA1 Cterminal) domains (Figure 7) [91]. Several cancer-associated mutations occur in these
domains that render BRCA1 unable to interact with its target effectors [91].
The sole defined enzymatic activity associated with BRCA1 occurs within its
RING domain, which functions as an E3 ubiquitin ligase [92]. Ubiquitination of target
substrates by BRCA1 requires interaction with an E2 ubiquitin-conjugating enzyme, and
is significantly enhanced by formation of a heterodimer between BRCA1 and the
BRCA1-associated RING domain protein (BARD1) [91]. Several targets of
BRCA1/BARD1-mediated ubiquitination have been identified, including CtIP, Claspin,
and Estrogen receptor alpha (ER-α) [93]–[95]. How these putative substrates are
recruited to the BRCA1/BARD1 E3 ligase complex and the biological relevance of their
ubiquitination in breast cancer remains unclear [90]. Recent in vivo studies have shown
that the ubiquitin ligase function of BRCA1 is dispensable for tumor suppression [96].
Thus, the biological consequences of BRCA1-mediated ubiquitination remain to be fully
understood.
The central region of BRCA1 encoded by exons 11-13 of the BRCA1 gene is
critical for the tumor suppressor function of BRCA1 [89]. It is within this domain that
BRCA1 becomes phosphorylated by ATM/ATR kinases in response to DNA damage,
which enables several proteins involved in DNA repair (Rad51, BRCA2), cell cycle
regulation (Rb) and transcriptional control (cMyc) to bind to this site [91], [97]–[100].
Additionally, the nuclear localization sequences of BRCA1 are contained within this
region [101]. Mutations within this central region of BRCA1 frequently involve loss of
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large portions of sequence, resulting in formation of a truncated protein that is unable to
form DNA repair complexes or bind transcriptional regulators [89].
The BRCT domains of BRCA1 mediate DNA binding capability and
phosphoprotein interactions involved in DNA damage repair (e.g. CtIP, Abraxas,
BACH1, p53) [102]. Several cancer-associated mutations occur in this domain, most
notably those that interfere with the binding of BRCA1 to p53, which is important for
p53-dependent transcription of p21 [63]. Additionally, it is within this domain that
BRCA1 interacts with the BRCA1-associated C-terminal helicase BACH1 [102].
BACH1 acts as a critical mediator of the BRCA1 DNA damage response by localizing
BRCA1 to sites of DNA damage and using its helicase activity to provide chromatin
access to BRCA1 and other members of the HR-mediated DNA repair complex [103].
Mutation or loss of BACH1 has been shown to disrupt BRCA1-mediated localization and
DNA repair function [104].
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Figure 7: BRCA1 protein structure.
BRCA1 contains an N-terminal RING domain that contains its nuclear export sequence
(NES) as well as the binding site for the BRCA1-associated Ring domain containing
protein BARD1, which shuttles BRCA1 to the nucleus and enhances its ubiquitin ligase
activity. The central region of the protein is encoded by exons 11-13 and contains the two
nuclear localization sequences (NLS) and target phosphorylation sites for ATM/ATR
kinases (SCD). Binding sites for the DNA repair proteins Rad50/51, BRCA2, PALB2,
the tumor suppressor Rb and the oncoprotein Myc are found within this central domain.
The two tandem C-terminal BRCT domains of BRCA1 contain binding sites for several
phosphoproteins, including the CtBP interacting protein (CtIP), Abraxas, BACH1/BRIP1
helicase, and the tumor suppressor p53.
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Figure 8: BRCA1-regulated pathways.
BRCA1 maintains genome integrity by forming a series of complexes that regulate DNA
repair, cell cycle progression, transcription, and ubiquitination. BRCA1 becomes
activated by ATM/ATR kinases in response to DNA damage and is able to interact with
its downstream targets. Some downstream targets of BRCA1 include: p53, Rb, CHK1,
and PLK1 (involved in cell cycle regulation; apoptosis), FANCD2 (cell cycle arrest;
homologous recombination), BARD1 (ubiquitination), XIST (X-chromosome silencing;
non-homologous end joining), and BACH1 (chromatin remodeling, homologous
recombination).
Figure copied with permission from [105] (Nature Publishing Group, license no. 3693130867077).
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BRCA1 in breast cancer
The role of BRCA1 in hereditary human cancer has been well studied [106]. Loss
of heterozygosity in carriers of a germline BRCA1 mutation results in complete loss of
BRCA1 function, leading to genomic instability [107]. Accumulation of DNA damage in
the absence of BRCA1-mediated DNA repair can either activate p53-dependent pathways
(leading to cell cycle checkpoint, growth arrest, and apoptosis or senescence) or facilitate
further mutations that inactivate tumor suppressors or activate oncogenes (leading to
carcinogenesis) [107].
The majority (~90%) of breast cancers are sporadic, and BRCA1 mutations are
rare in these cancers [87]. However, BRCA1 expression is suppressed in ~50% of
sporadic breast tumors, especially those that are highly malignant [67]–[69]. Allelic loss
and promoter hypermethylation of BRCA1 have both been demonstrated in sporadic
breast cancers and thus may account for the observed decrease in BRCA1 expression
[66], [108].

BRCA1 regulation by Ras
Recently, a role for BRCA1 was identified in Ras-induced senescence [64].
Activated Ras was shown to downregulate expression of BRCA1-binding partner
BACH1 helicase, leading to the dissociation of BRCA1 from chromatin [64]. Rasinduced hyperproliferation in the absence of BRCA1 DNA repair leads to genomic
instability, triggering a DNA damage response that promotes cellular senescence [109].
The genomic instability caused by Ras activation and subsequent BRCA1 inactivation
can also facilitate the acquisition of secondary oncogenic hits that allow certain cells to
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bypass senescence and become transformed [110]. Thus, BRCA1 dysregulation
contributes to Ras-induced senescence yet renders cells susceptible to senescence bypass
and transformation. Currently, no direct means of communication between BRCA1 and
Ras has been established.

BRCA1 and Her2
Her2 overexpression contributes to ~25-30% of Ras activation in human breast
cancer [12]. Similar to Ras, activated Her2 expression has been shown to suppress the
BRCA1-mediated DNA repair pathway and drive senescence [111]. These oncogeneinduced senescence pathways do not necessarily ensure complete growth arrest [62], and
can be subverted in favor of malignancy by accumulation of additional oncogenic hits
[64][110].
Her2 overexpression is not common in hereditary BRCA1 tumors, and the
majority of findings suggest either no association or an inverse correlation between Her2
overexpression and BRCA1 mutation in primary breast tumors [112]–[114]. However,
two reports have shown that BRCA1 loss in Her2-positive sporadic breast tumors is
associated with worse prognostic features (e.g. higher histological grade, increased
proliferation) and a poor survival rate [115], [116]. Moreover, one of these studies found
that 90% of the Her2-positive tumors in their experiments were in fact negative for
BRCA1 [116]. While further studies are clearly required to determine the frequency and
pathobiological characteristics of Her2+/BRCA1- tumors in sporadic breast cancer, the
existing data supports a plausible role for BRCA1 loss in the development of Her2mediated tumor formation.
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SUMMARY
Despite the paucity of Ras mutations, constitutive Ras activation is a frequent
occurrence in human breast cancer, largely as a result of overexpression of its upstream
activators (e.g. Her2) or inactivation of its negative regulators (e.g. Ras GAPs). Activated
Ras proteins are powerfully transforming, but can also promote apoptosis and
senescence. The paradoxical mechanism by which Ras can have both growth-promoting
and growth-inhibitory functions remains poorly understood, but is known to involve
activation of the tumor suppressors p53 and Rb [30] and requires expression of the
RASSF family member NORE1A.
NORE1A is a pro-apoptotic and pro-senescent effector of the Ras oncoprotein.
NORE1A localizes primarily to the nucleus where it acts as a scaffold for various Rasregulated interactions. The growth inhibitory properties of NORE1A and its frequent loss
in human cancers suggest that NORE1A is a tumor suppressor, though its mechanism of
action in tumor suppression is poorly defined.
BRCA1 is a tumor suppressor that plays a key role in DNA repair. Loss of
BRCA1 is associated with hereditary breast and ovarian cancer, and is also thought to
play a role in sporadic breast tumorigenesis.
Recently, BRCA1 was shown to play a role in Her2/Ras signaling by regulating
senescence induction by these oncogenes [64], [111]. However, loss of BRCA1 function
can also contribute to Ras-driven transformation [64]. The mechanism linking Ras and
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BRCA1 is not understood. The frequent inactivation of BRCA1 in Her2-positive sporadic
breast tumors suggests that loss of BRCA1 may also contribute to transformation in these
cancers.
I observed nuclear co-localization between the Ras-regulated tumor suppressors
NORE1A and BRCA1 in human tumor cells. Both of these proteins are frequently
inactivated in breast cancer. I designed a series of experiments to determine whether
NORE1A and BRCA1 could form a complex, whether they could cooperate to regulate
Her2/Ras senescence, and if their dual inactivation synergized to enhance Her2/Ras
transformation. Furthermore, I examined the role of NORE1A on a key tumor suppressor
function of BRCA1, its ability to mediate DNA DSB repair.
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MATERIALS AND METHODS

Plasmids and DNA.
NORE1A: Human NORE1A cDNA was obtained from Origene and confirmed by
sequencing. HA- and KATE-NORE1A expression plasmids were generated (courtesy of
Dr. Lee Schmidt) by cloning the full-length NORE1A cDNA as a BglII–EcoRI fragment
into a pcDNA vector with an HA epitope tag, pmKATE2 (Evrogen) and pEGFP-C1
(Takara Bio). NORE1A-INT domain was generated (courtesy of Dr. Lee Schmidt) by
cloning AA 170-272 of the full-length NORE1A cDNA as a BglII-EcoRI fragment into a
pCDNA vector with an HA epitope tag. All fusion proteins were under the control of a
CMV promoter. shRNAs for human NORE1A (described in [36]) were obtained from
Open Biosystems, and stable transfected cell lines were obtained after selection with
blasticidine-S-hydrochloride (5 µg/ml; Sigma-Aldrich).

BRCA1: YFP-BRCA1 was a gift from Dr. Ray White (Huntsman Cancer Institute, Utah).
shRNAs for human BRCA1 were obtained from Origene (SKU: TG314440), and stable
transfected cell lines were obtained after selection with puromycin dihydrochloride (1
µg/mL; Sigma-Aldrich).
Her2: HER2 CA (V659E) was a gift from Mien-Chie Hung (Addgene [117]), and stable
transfected cell lines were obtained after selection with G418 Sulfate (300µg/mL;
Cellgro).

BACH1: pcDNA3-myc-his-BACH1 was a gift from Ronny Drapkin (Addgene [118]).
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Tissue culture and cell lines.
Cell lines: HEK-293T and MCF-10A cells were obtained from the ATCC (Manassas,
VA). HEK-293T cells were grown in DMEM (Corning) with 10% FBS (Valley
Biomedical) and 1% penicillin/streptomycin (Corning). MCF-10A cells were grown in
DMEM/F12 medium (Corning) supplemented with 5% horse serum (Gibco), 1%
penicillin/streptomycin (Corning), 0.5mg/mL hydrocortisone (Sigma-Aldrich), 20ng/mL
human epidermal growth factor (EGF) (Sigma-Aldrich), and 10µg/mL human insulin
solution (Sigma-Aldrich).
Transfections: Stable transfectants were generated by transfecting cells each with 2µg of
plasmid DNA using jetPRIME (PolyPlus) transfection reagent. Plasmid DNA was
combined in a microcentrifuge tube with 200µL jetPRIME buffer and 4µL of jetPRIME
reagent, mixed thoroughly and allowed to incubate for 10 min at room temperature.
Transient transfections were performed by transfecting cells each with 1µg of plasmid
DNA using jetPRIME as above. Medium was changed 24 hours after transfection, and
cells were allowed to grow for an additional 24 hours.
Generation of stable MCF10A cell lines: Matched sets of MCF-10A NORE1A-/BRCA1cells were generated using stable sequential transduction. First, MCF10A cells were
seeded to confluency in 100mm dishes, transfected with either 2µg of shRNA against
BRCA1 or a scrambled pRS-vector control, and then allowed to grow at 37C for 2 days.
Fresh growth medium (10 mL + 1 µg/mL puromycin dihydrochloride) was applied every
day for ~2 weeks until only puromycin resistant cells remained. These cells were then
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trypsinized and plated on a new 100mm dish and allowed to recover for 2 passages. Next,
BRCA1- and scr control cells were plated in 100mm dishes and transfected with either a
bRS-vector scrambled control or shRNA against NORE1A, then allowed to grow for 2
days at 37C. These cells were then selected with 10mL media + 5 µg/ml blasticidine-Shydrochloride (in the same manner as before) for ~2 weeks until only blasticidineresistant cells remained. These cells were allowed to recover for 2 passages. This resulted
in a matched set of 4 MCF-10A cell lines: scr/scr (vector control), vec/shBRCA1
(BRCA1-), vec/shNORE1A (NORE1A-), shBRCA1/shNORE1A (BRCA1-/NORE1A-).
In addition, a constitutively activated mutant of Her2 (V659E) was stably transfected into
a set of each of these 4 cell lines. Her2+ cells were selected using 300µg/mL G418
Sulfate in 10mL growth media in the same manner as above for ~2 weeks. All cells were
allowed to recover for 2 passages. The end result was two matched sets of MCF-10A
NORE1A-/BRCA1- cell lines, one Her2+ and one without Her2.
Growth curves: MCF-10A standard growth curves were performed by plating 2x104 cells
per 60mm dish (Cellstar), and cells from each set were trypsinized (0.25% Trypsin;
Corning) and counted manually at the same time each day for four days.
Soft agar assays: Soft agar assays were performed by resuspending 104 MCF-10A cells in
standard soft agar mix (0.5mL penicillin/streptomycin (Corning), 1.8mL 10X PBS,
1.6mL serum (Gibco), 30mL DMEM/F12 medium (Corning), 16mL melted agar (Difco))
and plating them on a pre-hardened 0.7% agar base in 12-well plates (Cellstar).
Anchorage-independent growth was determined by manually counting the number of
colonies formed in agar 2 weeks after plating the cells.
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Senescence assays: β-galactosidase assays were performed using a BioVison kit
(BioVision). 104 MCF-10A cells were plated in 12-well plates, fixed with 0.5mL of
fixing solution for 15 min at room temp, washed twice with 1X PBS, and stained
overnight at 37C with 0.5mL staining solution (470µL staining reagent, 5µL staining
supplement, 25µL of 20mg/mL X-Gal in DMF). Senescent cells were observed and
imaged using an IX50 inverted system microscope (Olympus) with a UPlanFl 4×/0.13
PhL or LCPlanFl 20×/0.40 Ph1 objective (Olympus).
Anoikis assays: Anoikis assays were performed as described in [119] [120]. Tissue
culture wells of a 12-well plate (Cellstar) were coated with 12mg/ml Poly-HEMA
(Sigma-Aldrich) in 95% ethanol (BDH) and allowed to dry overnight. 2x105 MCF-10A
cells/well in 1mL growth medium were added to each well and plates were incubated at
37C for 48 hours. Apoptosis induction through loss of cell attachment was measured by
mixing 0.5mL of cell suspension with 0.1mL of 0.4% Trypan Blue solution (Life
Technologies), filling a hemocytometer, and manually counting the number of viable and
non-viable cells. These results were compared to viability counts for control cells grown
simultaneously in 12-well plates without Poly-HEMA coating.
Replication stress: To induce replication stress, HEK-293T cells were treated with 2mM
hydroxyurea (Sigma-Aldrich) in cell culture media for 6 hours as described in [121].
Comet assays: Sub-confluent MCF-10A cells were treated with doxorubicin
hydrochloride (0.3 µg/mL; Sigma-Aldrich) for 24 hours to induce DNA damage. DNA
damage was then assayed using a CometAssay Kit (Trevigen). Cells were harvested and
resuspended at 1 x 105 in sterile PBS, and combined at a ratio of 1:10 with molten
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LMAgarose. 50µL of the cell/agarose mixture was plated on a CometSlide and allowed
to cool for 30 min at 4C. Slides were then immersed in 4C lysis solution for 1 hour, and
then immersed in Alkaline Unwinding solution (0.4g NaOH, 250µL 200mM EDTA,
49.75mL dH2O) for 1 hour at room temperature in a sealed plastic Coplin staining jar.
Slides were then placed immersed in ~800mL Alkaline Electrophoresis solution (8g
NAOH, 2mL 500mM EDTA, 1L dH2O) in an electrophoresis tray and power supply was
set to 21 volts for ~30 minutes. Electrophoresis solution was drained from slides, and
they were gently immersed 2 x 5 min in H2O and then 1 x 5 min in 70% EtOH. Slides
were then dried for ~45 minutes at 37C and the dried agarose was stained with 100µL of
SYBR green DNA stain (ThermoFisher Scientific) for 30 min at room temp in the dark.
Slides were tapped gently to remove excess stain, rinsed briefly in dH2O and allowed to
dry completely at 37C (~30min). Slides were then visualized on an Olympus
fluorescence inverted microscope or an Evos FL Cell Imaging System (ThermoFisher
Scientific) at 100x magnification. Comet tails from 100 (randomly selected) cells were
scored using OpenComet software for ImageJ based on their DNA content (intensity)
[122]. DNA damage was quantified as comet tail moment, defined as the product of the
tail length and the fraction of total DNA in the tail.
Fluorescent microscopy: GFP and RFP proteins were visualized at room temperature in
live cells in growth medium using an IX50 inverted microscope (Olympus) with a
UPlanFl 100×/1.3 oil immersion objective (Olympus) and a SPOT camera (Diagnostic
Instruments Inc.)
Antibodies.
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Monoclonal and polyclonal NORE1A antibodies have been described previously [36].
The PAS 17072 NORE1A antibody was used at 1:500 dilution in 5% powdered milk +
TBST. Mouse monoclonal HA antibodies (used at 1:5k dilution in 5% milk + TBST)
were obtained from Covance, and mouse monoclonal GFP and BRCA1 antibodies (1:200
dilution in 5% milk + TBST) were from Santa Cruz Biotechnology, Inc. Mouse
monoclonal β-actin antibodies (1:10k dilution in 5% milk + TBST) were obtained from
Sigma-Aldrich. Rabbit polyclonal p21 and Her2 (1:1k dilution in 5% BSA + TBST)
antibodies were obtained from Cell Signaling Technology. Mouse monoclonal c-Myc
(1:5k dilution in 5% milk + TBST) antibodies were obtained from Thermo Scientific.
Goat anti–mouse and anti–rabbit secondary antibodies conjugated to peroxidase (used at
1:10k-20k dilution in TBST) were obtained from Thermo Fisher Scientific.

Western analysis and immunoprecipitation.
Signaling assays: MCF-10A cells were seeded at confluence and grown in a 37C
incubator overnight. Cells were lysed in 100 µL RIPA buffer (Sigma-Aldrich) with
sodium orthovanadate (Sigma-Aldrich) and protease inhibitor cocktail (Sigma-Aldrich
cat # P8340) added just prior to lysis, and the concentration of protein in the lysates was
quantified using a Bio-Rad protein assay (Bio-Rad) using a spectrophotometer (abs: 595).
Equal amounts of protein lysate were combined 1:1 with Laemmli Sample Buffer (BioRad) and 16-20 µL total was loaded onto a 4-15% Tris-glycine gel (Bio-Rad) and run for
~1 hr at 120 volts using a Mini-PROTEAN electrophoresis system (Bio-Rad). Gels were
then transferred at 4C for ~4 hours at 20 volts to a 0.2µm nitrocellulose membrane (BioRad). Membranes were blocked at room temperature for 1 hr in 5% powdered milk +
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TBST solution and incubated in the appropriate primary antibody (1:200-1:10,000) in 5%
milk + TBST or 5% BSA + TBST solution overnight at 4C, washed 5 x 5min in TBST
(Tris-buffered saline (Corning), 0.1% Tween 20 (Sigma-Aldrich)), incubated with the
appropriate secondary antibody (1:10,000-1:20,000) in TBST for 1 hr, and washed again
for 5 x 5 min in TBST. Nitrocellulose membranes were then incubated in 4 mL of Pierce
ECL solution (2 mL of stable peroxide solution + 2 mL of luminol/enhancer solution;
Thermo Scientific, Rockford, IL) for 2-5 minutes with constant rocking, placed inside a
standard film cassette and developed using X-Ray film (MidSci, Valley Park, MO).

Co-immunoprecipitation: Cells were lysed in 100-200 µL modified RIPA buffer (150mM
NaCl, 50mM Tris (Cellgro), pH 7.5, 1% Tergitol NP-40 (Sigma-Aldrich)) with protease
inhibitors added prior to lysis as above. Precleared lysates were immunoprecipitated
overnight with GFP-Trap agarose beads (Allele Biotech, San Diego CA) or primary
antibody as appropriate and washed 3 x 3min with lysis buffer, then Western blotted as
above.

Image acquisition and processing.
All images were scanned and quantified using a Pharos FX plus Molecular Imager (BioRad) and Quantity One software (Bio-Rad) or ImageJ software. Linear range was
determined for individual antibodies by plotting the quantitated densities of Western
blotted bands against the initial amount of protein lysate loaded in each lane. To control
for variability, the background-subtracted densities of each protein of interest and
normalizing control (e.g. beta-actin) were quantified and protein of interest values were
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divided by relative normalized control values in their respective lanes. For quantitative
experiments, each condition was performed in duplicate or triplicate as described. For
statistical comparison, one-way analysis of variance (ANOVA) was used to determine if
mean differences existed across groups (ctrl, shB, shN, shBN) following each
experimental condition. The null hypothesis used was that all means were equal. If at
least two means were identified as significantly different (critical value method = F>Fcrit
or p-value method = p < 0.05), post hoc Student’s t-tests were applied. Averages, pvalues, and fold-changes were calculated and the results graphed using Excel (Microsoft).
Images were compiled using PowerPoint (Microsoft) or Photoshop (Adobe).

39

CHAPTER V: NORE1A AND BRCA1 FORM A HER2-REGULATED
ENDOGENOUS COMPLEX

1. INTRODUCTION
Ras is constitutively activated in breast cancer.
Mutational activation of the Ras oncogene is found in ~1/3 of all human cancers,
making Ras the most common oncogene in human cancer [123]. Ras mutations are
infrequent in breast cancer [48]–[50]; however, persistent upstream signaling by the
growth factor receptor Her2 results in constitutive activation of wild-type Ras in ~2530% of human breast cancers [11]–[13]. Mutations in Ras GAPs (e.g. NF1, RASAL2,
and DAB2IP) lead to constitutive Ras activation in up to 50% of human breast cancers
[14]–[16]. Thus, the Ras signaling pathway is hyperactivated in a large percentage of all
human breast cancers.

Her2 and Ras activation can drive senescence or transformation.
Constitutive activation of Ras drives growth and transformation by binding and
activating multiple effectors that stimulate various mitogenic pathways, the best
characterized of which are the Raf and PI3K pathways [17]. Accordingly, activation of
Her2 can also promote transformation via Ras signaling pathways [11], [52], [124],
[125]. Paradoxically, activation of Her2 and Ras can also promote cellular senescence, an
irreversible cell growth arrest [30], [59]. This oncogene-induced senescence represents an
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early barrier to Her2/Ras transformation, and is thus an important tumor suppressor
mechanism in vivo [126]. In order to become cancerous, cells must acquire mutations or
epigenetic changes that allow them to subvert the senescence program. The mechanism
by which activated Her2/Ras drives senescence and how this is bypassed during
transformation remains poorly understood [127].

NORE1A is a critical Ras senescence effector.
NORE1A (RASSF5) is a member of the Ras-association domain family (RASSF)
of tumor suppressors that binds activated Ras and mediates its growth inhibitory
properties [36][81][86]. NORE1A is frequently downregulated in primary human tumors
and breast cancer cell lines by promoter hypermethylation [65], and a translocation
involving NORE1A is associated with a hereditary human cancer syndrome [85]. Thus,
NORE1A acts as a tumor suppressor, though its mode of action in tumor suppression and
Ras-mediated growth inhibition remains poorly understood.
NORE1A lacks enzymatic activity and has been shown to act as a scaffolding
molecule [36]. Similar to other RASSF proteins, NORE1A can bind the proapoptotic
MST kinases which begin the canonical Hippo pathway [80]. However, the interaction
with MST is not required for NORE1A tumor suppressor activity [81], suggesting that
other interactions are key to this function. Although NORE1A overexpression can induce
apoptosis, when expressed at more physiological levels NORE1A induces cell cycle
arrest by promoting the p53-mediated activation of p21 [40].
In the presence of activated Ras, NORE1A acts as a critical component in Rasmediated senescence signaling to p53 [36]. NORE1A facilitates Ras senescence by
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scaffolding p53 in a nuclear complex with the kinase HIPK2 that mediates the prosenescent acetylation of p53 [36]. Loss of NORE1A (at least, partially) uncouples Ras
from p53 and abrogates its ability to induce senescence [36], [40]. Consequently, loss of
NORE1A expression can facilitate senescence bypass and transformation in response to
activated Ras signaling.

BRCA1 plays a role in Her2/Ras senescence
Oncogene-induced senescence is often characterized by the accumulation of DNA
double strand breaks (DSBs) [109], [126]. This is largely due to replication fork stalling
and collapse caused by aberrant DNA replication in response to hyperactive Ras
signaling [126]. Under normal conditions, DNA DSB accumulation would lead to
initiation of checkpoint activation, cell cycle arrest, and formation of DNA repair
complexes at stalled replication forks mediated by the breast cancer susceptibility protein
BRCA1 [128]. However, activation of Her2/Ras suppresses BRCA1-mediated DNA
repair [64][111]. Oncogene-induced hyperproliferation in the absence of BRCA1 DNA
repair mechanisms produces sufficient replication stress and accumulation of DNA DSBs
to initiate a senescence response [64][111]. The role of BRCA1 in Her2/Ras-mediated
senescence remains ill defined [129], as currently no direct mechanism of communication
between Ras and BRCA1 has been identified.

Summary
Both NORE1A and BRCA1 mediate Ras senescence, modulate p21 expression,
and are downregulated in breast cancer. The connection between Her2/Ras and BRCA1
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is not known. I decided to examine the possibility that NORE1A might connect Ras (and
therefore, Her2) to BRCA1. Using activated Her2 as a model of constitutive Ras
signaling, I now show that NORE1A and BRCA1 form a physiological, Her2-regulated
complex in human cells. In response to aberrant Her2/Ras signaling, NORE1A appears to
localize BRCA1 to stalled replication forks. Thus, the cellular levels of NORE1A may
dictate how Ras mediates the localization and function of BRCA1. Moreover, the
interaction with BRCA1 may regulate the tumor suppressor activity of NORE1A in
breast cancer.
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2. RESULTS
NORE1A and BRCA1 co-localize in the nucleus.
NORE1A functions as a scaffolding molecule, and has been shown to promote the
nuclear localization and activation of the tumor suppressor p53 [40]. BRCA1 contains
two nuclear localization sequences (NLS) that mediate its transport from the cytosol to
the nucleus (Figure 7). The nuclear localization of BRCA1 is important for its tumor
suppressor ability [130], as loss of this localization renders BRCA1 unable to participate
in DNA repair and subsequently leads to an increase in unrepaired mutations and
chromosomal abnormalities [91]. Accordingly, in nearly all primary breast tumors and
breast cancer cell lines that express BRCA1, it is largely localized in the cytoplasm [131].
To determine if NORE1A expression could alter the subcellular localization BRCA1, I
overexpressed RFP-tagged NORE1A and YFP-tagged BRCA1 in HEK-293T cells.
Figure 9 shows that BRCA1 and NORE1A co-expression shifted a fraction of total
cellular BRCA1 into nuclear foci with NORE1A, suggesting that NORE1A is recruiting
BRCA1 to these nuclear foci.
Although

breast

cancer

seldom

exhibits

Ras

mutations,

mutation

or

overexpression of the upstream Ras activator Her2 occurs in 25-30% of all breast cancers
[12]. NORE1A is a direct effector of Ras, and BRCA1 has also been shown to play a role
in Ras signaling [64]. To determine whether Her2 (and thus Ras) signaling could regulate
NORE1A/BRCA1 co-localization, I overexpressed a constitutively activated Her2 mutant
(V659E) in HEK-293T cells with my fluorescently tagged NORE1A and BRCA1. Figure
9 shows that addition of Her2 (V659E) enhanced the size of the observed nuclear foci

44

formed by NORE1A/BRCA1 co-localization, suggesting that Her2/Ras signaling
enhances the ability of NORE1A to recruit BRCA1 to the nucleus.
Activation of oncogenes like Her2 or Ras promotes hyperproliferation, which can
lead to replication stress induced by deoxyribonucleotide pool depletion [132][133].
BRCA1 responds to this replication stress by forming protein complexes at stalled
replication forks to protect and repair damaged DNA [134]. Since NORE1A can promote
the nuclear localization of BRCA1 in the presence of activated Her2 signaling, I
wondered if these proteins were co-localizing at stalled replication forks in response to
oncogene-induced replication stress. To determine if this was the case, I treated cells coexpressing YFP-BRCA1 and RFP-NORE1A with 2mM hydroxyurea (HU) for 6 hours, as
described in [135]. HU depletes cells of dNTP pools, which slows/stalls replication
machinery, generating a replication stress response [135]. Thus, HU treatment promotes
replication stress via a similar mechanism as activated Her2/Ras. Figure 9 shows that
hydroxyurea-induced replication stress enhanced NORE1A/BRCA1 co-localization at
nuclear foci.
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Figure 9: NORE1A and BRCA1 co-localize after replication stress.
HEK-293T cells were transfected with GFP-vector or YFP-tagged BRCA1 and RFPNORE1A, in the presence or absence of Her2 (V659E), and images were captured 24
hours later using a fluorescence microscope (magnification = 1000x). A group of cells
were also treated with 2mM hydroxyurea (HU) for 6 hours.
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NORE1A and BRCA1 form an endogenous Her2 and Ras-regulated complex.
NORE1A is a direct Ras effector that mediates the growth inhibitory properties of
Ras. BRCA1 functions as a tumor suppressor by forming protein complexes in the cell
important for maintaining genome integrity [91], and can also play a role in Her2/Ras
signaling [64][111]. Currently, no direct mechanism of communication between Ras and
BRCA1 has been discovered. Since I observed NORE1A recruiting BRCA1 to nuclear
foci in response to activated Her2 (and thus Ras) signaling, I wondered whether Her2
could regulate their complex formation. This would suggest the existence of a
Her2/Ras/BRCA1 signaling pathway.
To determine if NORE1A and BRCA1 could form a physiological complex in
human mammary cells, I stably transfected MCF-10A cells with Her2 (V659E) or a
vector control, immunoprecipitated cell lysates with NORE1A, and immunoblotted for
BRCA1. In the absence of activated Her2 I was able to detect a modest association
between endogenous NORE1A and BRCA1 proteins. However, when cells were stably
transfected with activated Her2, the association of endogenous NORE1A with
endogenous BRCA1 was greatly enhanced (Figure 10A). As further confirmation,
exogenous expression of NORE1A and BRCA1 in HEK-293T cells challenged with
activated Ras (K12V) or Her2 (V659E) gave similar results (Figure 10B).
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Figure 10: NORE1A and BRCA1 form a Her2 and Ras-regulated complex.
(A) Equal amounts of protein lysate from MCF-10A human breast epithelial cells stably
transfected with Her2 (V659E) or a vector control were immunoprecipitated (IP) with
anti-NORE1A antibody, fractionated on an SDS-polyacrylamide gel, and then
immunoblotted (IB) for the presence of BRCA1 in the complex. Cell lysate
immunoprecipitated with IgG alone and lysis buffer immunoprecipitated with NORE1A
antibody were used as negative controls. (B) HEK-293T cells were transiently transfected
with either YFP-tagged BRCA1 or HA-tagged NORE1A in the presence or absence of KRas12V or Her2 (V659E) expression constructs. Cells were lysed 24 hours after
transfection and equal amounts of protein were immunoprecipitated for GFP. The
immunoprecipitate was fractionated on an SDS-polyacrylamide gel and then
immunoblotted with anti-HA and anti-GFP antibodies. Fold change was calculated after
normalizing to total HA-NORE1A expression levels in addition to total BRCA1
expression levels. Figure is representative of 2 independent experiments.
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BRCA1 binds the INT-domain of NORE1A.
NORE1A has several protein binding domains that have been identified,
including a Ras-binding domain and C-terminal SARAH domain that binds the MST
kinases (Figure 5). In addition, NORE1A contains a stretch of ~100aa that lies between
the DAG/PE binding domain and Ras-association (RA) domain which my laboratory has
termed the intermediate (INT) domain (Figure 11A). This domain is relatively
uncharacterized, but does contain several putative phosphorylation sites, as predicted by
the Netphos tool (sensitivity 69-96%) [136]. These include S177 (score = 87%), S182
(99%), T186 (87%), T202 (98%), and S260 (99%).
To further characterize the interaction between NORE1A and BRCA1, I cooverexpressed serial deletions of NORE1A with full-length BRCA1 in HEK-293T cells. I
determined that BRCA1 could interact with the INT domain of NORE1A (Figure 11B).
Since the INT domain is a fragment of the full-length NORE1A protein that can bind
BRCA1, I hypothesized that it could be used as a dominant-negative for the
NORE1A/BRCA1 interaction. Specifically, that overexpression of the INT domain might
block the binding of full-length NORE1A to BRCA1. Since NORE1A and BRCA1 act as
tumor suppressors in the cell, I hypothesized that blocking their interaction could have a
transforming effect on cells.
To determine whether overexpression of the INT-domain had an effect on the
morphology or growth of non-transformed cells, I stably overexpressed the INT-domain
into MCF-10A human mammary epithelial cells, which are non-transformed. I observed
that overexpression of the INT-domain in these cells caused them to exhibit a
transformed phenotype, as indicated by their enhanced ability to grow under anchorage-

50

independent conditions in soft agar compared to control MCF-10A cells (Figure 11C).
Thus, overexpression of a fragment of the tumor suppressor NORE1A—that I have
shown can bind BRCA1—had a transforming effect. This is, to my knowledge, the first
identification of a transforming capacity in a RASSF tumor suppressor. This result also
implies that blocking the NORE1A/BRCA1 interaction could be transforming. Further
experiments are required to determine if this is the case.
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Figure 11: BRCA1 binds the INT-domain of NORE1A.
(A) Location of the NORE1A-INT domain within the full-length NORE1A protein and
its ~100 AA sequence. Asterisks indicate potential S/T phosphorylation sites (score
>97% [136]). (B) HEK-293T cells were transiently transfected with either GFP-tagged
BRCA1 or NORE1A-INT expression constructs. Cells were lysed 24 hours after
transfection and equal amounts of protein were immunoprecipitated (IP) for GFP. The
immunoprecipitate was fractionated on an SDS-polyacrylamide gel and then
immunoblotted (IB) with anti-HA and anti-GFP antibodies. (C) MCF-10A cells stably
transfected with HA-vector or HA-tagged NORE1A-INT domain were plated in soft agar
and grown for 2 weeks at 37C. Representative images are from 2 independent
experiments performed in duplicate.
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3. DISCUSSION
Ras is the most frequently mutated oncogene in human cancer. The low
percentage of breast cancers with Ras mutations led to the theory that Ras does not play
an important role in breast tumorigenesis [11]. However, the Ras signaling pathway is
constitutively activated in over half of all breast tumors due to persistent upstream
signaling by the EGFR family member Her2 [11], [124], [125] or certain Ras GAPs [14]–
[16].
Her2 overexpression is an early-occurring and highly transforming event in breast
cancer [52]. Her2+ breast cancers usually have much worse prognosis and propensity for
metastasis than non-Her2 breast cancers [55]–[57]. The majority of Her2+ primary breast
tumors have lost expression of the tumor suppressor BRCA1 [115], [116]. This is
paradoxical, as Her2 or Ras-mediated inactivation of BRCA1 in non-transformed cells
promotes senescence [64], [111]. Therefore, additional oncogenic mutations must be
occurring that are allowing these Her2+/BRCA1- cells to bypass senescence and undergo
transformation.
The most important tumor suppressor function of BRCA1 is its ability to localize
to the nucleus in response to replication stress and participate in DNA repair [137]. In
nearly all primary breast tumors and breast cancer cell lines that retain BRCA1
expression, it is predominantly localized to the cytoplasm [131]. I have shown that Her2
overexpression can promote the nuclear localization of BRCA1 in human tumor cells. In
addition, Her2 promoted the co-localization of BRCA1 with the Ras effector NORE1A.
NORE1A has been shown to act as a nuclear localization factor for the tumor suppressor
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p53 [40]; thus, I hypothesized that NORE1A was recruiting BRCA1 to the nucleus in
response to aberrant Her2/Ras activation.
NORE1A appears to be acting as a direct communication link between BRCA1
and Ras signaling. I showed that NORE1A forms an endogenous, Her2/Ras-regulated
complex with BRCA1 that mediates its subcellular localization. Thus, the interaction
between these two proteins is physiological, though whether it is occurring directly or as
part of a larger DNA repair complex remains to be determined.
I mapped the BRCA1 binding domain down to a ~100 amino acid region of the
full-length NORE1A protein that my laboratory termed the NORE1A-INT domain. This
domain was previously shown to be indispensible for NORE1A-mediated growth
inhibition [81]. However, the mechanism of action of the INT domain remains to be fully
investigated. Using an artificial neural network that predicts phosphorylation sites [136],
I found several putative consensus phosphorylation sites for S/T kinases within the INT
domain, suggesting that it may serve as a potential interaction site of NORE1A with
numerous kinases. Two of these consensus phosphorylation sites (T202 and S260) are
particularly interesting, as NORE1A contains a nuclear localization sequence in this
region of the INT domain (aa 200-260). Phosphorylation of NORE1A has been shown to
regulate its subcellular localization, and subsequently its function within the cell [73]–
[75]. Thus, kinase interactions within the INT domain could regulate the subcellular
localization of NORE1A. This could explain previous reports that the INT domain was
indispensible for growth inhibition [81].
My observation that overexpressing the INT domain in MCF-10A nontransformed human breast epithelial cells caused these cell to exhibit a transformed
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phenotype is, to my knowledge, the first identification of a transforming capacity in a
RASSF tumor suppressor. One possibility is that the INT domain is competing with fulllength NORE1A for binding to BRCA1, and overexpressing the INT domain is
effectively blocking the NORE1A/BRCA1 interaction. Whether blocking the
NORE1A/BRCA1 interaction is transforming is not known; however, this could be
determined by knocking down expression of NORE1A and BRCA1 in a non-transformed
cell line.
BRCA1 and NORE1A are both frequently inactivated in human tumors by
promoter hypermethylation [65], [66]. The rate of their co-inactivation in breast cancer is
not known. I hypothesize that co-inactivation of NORE1A and BRCA1 would result in
decreased senescence induction by activated Her2/Ras, likely contributing to the worse
prognosis seen in Her2+ breast tumors. The expression status of NORE1A/BRCA1 in
these tumors may be difficult to determine by methylation analysis alone, as NORE1A
can also be regulated at the mRNA [138] and protein levels [139]. Protein array analysis
from breast tissue tumor samples would be necessary to determine more accurate
NORE1A/BRCA1 expression levels.
Thus, I identify a novel Her2-Ras-NORE1A-BRCA1 pathway that links activated
Her2 and Ras signaling to BRCA1. This pathway has the potential to be constitutively
activated in over half of all breast cancers due to the high frequency of aberrant Her2/Ras
activation in these cancers.
I propose a scenario in which NORE1A and BRCA1 form a complex to repair or
maintain integrity of stalled replication forks in response to the increase in proliferation
stimulated by physiological Her2/Ras activation. The role of NORE1A/BRCA1 complex
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formation in Her2/Ras-mediated human breast tumorigenesis remains to be determined.
Since NORE1A and BRCA1 act as barriers to Ras transformation, loss of complex
formation between these tumor suppressors could shift the balance of Her2/Ras signaling
from pro-senescent to pro-tumorigenic during breast cancer formation.
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CHAPTER VI: NORE1A AND BRCA1 FORM A TUMOR SUPPRESSOR COMPLEX

1. INTRODUCTION
Constitutive Her2/Ras activation can drive senescence or transformation.
Constitutive activation of Ras signaling pathways occurs in over half of all breast
cancers, for the most part due to mutation or amplification of its upstream activator Her2
[11]–[16]. Up to 90% of Her2+ sporadic breast tumors are negative for BRCA1
expression, and these tumors have a worse prognosis and poorer survival rate than nonHer2+ tumors [115], [116]. The underlying paradox is that Her2/Ras activation or
BRCA1 inactivation in normal cells promotes senescence [59], [64]. Thus, loss of
additional senescence regulators must be occurring that are driving these cells toward
malignancy.
Aberrant activation of Her2/Ras induces hyperproliferation, which triggers a
DNA damage response that drives premature senescence in cells as a precaution against
malignant transformation [109], [140]. This oncogene-induced senescence induction is
characterized by an upregulation of certain tumor suppressor pathways, like the p53-p21
and p16-Rb pathways.
Once cells have become immortalized, their response to activated Ras signaling
changes. For example, activation of Her2 and Ras in MCF-10A human mammary
epithelial cells (which have reactivated telomerase [141]) promotes the biomarkers of
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senescence (e.g. enhanced SA-β-gal activity and upregulation of p21) yet fails to trigger
irreversible growth arrest [62]. This state of incomplete senescence (referred to as the
SWING state by Sherman et al.) is stable, and is suggested to be an intermediary step
between activation of oncogenes and cellular senescence or transformation [62].
Accordingly, cells residing in the SWING state can be manipulated to senesce or
transform via enhanced genotoxic stress or loss of p53-p21 signaling [62].

Her2/Ras senescence requires activation of p21.
Her2/Ras-driven senescence is dependent on the upregulation of p21, and does
not occur in p21- or p53-knockdown cells [142]. Similarly, formation of the intermediary
SWING state in MCF-10A cells is dependent on Her2/Ras-induced upregulation of p21
[62][111]. Thus, in order for immortalized MCF-10A cells (which lack p16) to bypass
senescence, they must lose the ability to activate p21.
Expression of p21 is tightly controlled by the tumor suppressor p53, through
which p21 mediates G1 cell cycle arrest in response to various cellular stressors [143]. In
response to oncogene activation, p53 becomes activated and transactivates p21 to drive
senescence [144], [145]. Nuclear localization of p53 is critical for its transactivation
function, and its sequestration in the cytoplasm has been observed in human tumors
[146].
The tumor suppressor and Ras senescence effector NORE1A plays a key role in
regulation of the cell cycle by p53-p21 signaling. In response to Ras activation, NORE1A
binds p53 and promotes its nuclear localization, leading to the upregulation of p21 and
induction of senescence [36], [40]. NORE1A loss in primary human tumors has been
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shown to tightly correlate with loss of p21 expression [40]. Thus, NORE1A is critical
regulator of Ras senescence that connects Ras to p53-p21 signaling.
Overexpression of the DNA repair protein BRCA1 can also regulate p53/p21
signaling. BRCA1 interacts directly with p53 [63] and can act as a coactivator of p21
transcription in response to DNA damage [147]. Interestingly, loss of expression of
BRCA1 can also activate p53-p21 signaling by triggering a DNA damage response that
promotes senescence [64]. This appears to be part of a controlled suicide response to
oncogene activation, as both aberrant Her2 and Ras signaling can promote BRCA1
inactivation [64], [111]. Thus, under physiological conditions BRCA1 can activate p53p21 signaling to temporarily stall the cell cycle, and under aberrant conditions BRCA1
loss activates p53-p21 signaling to shut down the cell cycle.
The “Goldilocks” response and senescence
Both activation of Her2/Ras and inactivation of BRCA1 can drive senescence
[62], [64], [111], [148]. In other words, cells are programmed to commit suicide in
response to genomic stressors like “too much” oncogene (Her2/Ras) activation or “too
little” tumor suppressor (BRCA1) expression in order to avoid malignancy. This effect
where senescence is initiated in response to elevated Her2/Ras or inactivated BRCA1 is
hereafter referred to as the “Goldilocks” response.
I provided evidence in Chapter V that suggested the existence of a
Her2/Ras/NORE1A/BRCA1 signaling pathway. NORE1A is required for senescence
after Ras activation [41]. Since Her2 lies upstream of Ras and signals through Ras
pathways [11], [12], I was curious to determine if NORE1A could monitor the senescent
response to Her2 activation via the same pathway. Since I showed that NORE1A could
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link BRCA1 to Ras signaling, I also wondered whether NORE1A was required for
BRCA1 to drive senescence after oncogene activation. Thus, I hypothesized that
NORE1A was monitoring the “Goldilocks” response that drives oncogene-induced
senescence.

Summary
In the preceding chapter I introduced a physiological, Her2/Ras regulated
interaction between NORE1A and the breast cancer associated protein BRCA1.
Her2/Ras-mediated inactivation of BRCA1 was shown to enhance p21 expression and
promotes senescence [64], [111]. I hypothesized that inactivation of NORE1A would
impair this Her2/Ras/BRCA1 senescence pathway.
I show here that NORE1A inactivation suppresses Her2+ senescence, and that
dual inactivation of NORE1A and BRCA1 has a synergistic effect on Her2/Ras
transformation. Furthermore, I show that dual inactivation of NORE1A and BRCA1 is
sufficient to transform MCF-10A cells in the absence of additional stimuli. This is due in
part to anoikis resistance in these cells. This data suggests that NORE1A monitors the
“Goldilocks” response to Her2/Ras activation and BRCA1 inactivation; NORE1A
expression must be “just right”, or cells cannot activate apoptosis or senescence in
response to these stressors and instead will become transformed.
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2. RESULTS
Generation of NORE1A/BRCA1 stable double knockdown cells.
I showed previously that NORE1A and BRCA1 form a Her2/Ras-regulated
complex in MCF-10A cells. To examine the role of NORE1A and BRCA1 complex
formation in neoplastic transformation of these cells, I generated a matched set of stable
NORE1A/BRCA1 double knockdown clones by sequential shRNA vector transduction,
which resulted in 80% BRCA1 depletion in BRCA1 knockdown cells, 60% NORE1A
depletion in NORE1A knockdown cells, and 91% NORE1A and 96% BRCA1 depletion
in the double knockdown cells (Fig. 12A). Standard growth analysis revealed that
individual depletion of NORE1A or BRCA1 enhanced the proliferation of MCF-10A
cells ~1.5-fold and ~2.5 fold, respectively, compared to vector control cells, and dual
depletion of NORE1A and BRCA1 had an additive effect (Fig. 13). This suggests that
dual inactivation of these proteins is having an effect on cell cycle regulation.
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Figure 12: Generation of MCF-10A knockdown cell lines.
(A) Western blot analysis of NORE1A and BRCA1 expression in MCF-10A
immortalized human mammary epithelial cells. Expression levels of NORE1A and
BRCA1 were quantified after sequential stable transduction of shRNA against NORE1A
or BRCA1 or a scrambled control into these cells. The density of the bands was
quantified using ImageJ software and relative BRCA1 or NORE1A expression was
calculated after normalizing to β-actin expression. (B) Western blot analysis of Her2
expression in shBRCA1/shNORE1A MCF-10A cells. Her2 (V659E) was stably
overexpressed in the matched set of MCF-10A knockdown cells from (A) and its
expression was validated by Western blot.
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Figure 13: Depletion of NORE1A or BRCA1 enhances growth of MCF-10A cells.
Matched sets of knockdown MCF-10A cells were plated at 2x104 and grown in 2D
culture for 4 days. Cells were trypsinized and counted each day. (bottom) Relative
changes in growth between each set at Day 4 expressed as a bar graph. Data represent the
mean ± SD of duplicate experiments. Data that are significantly different are indicated by
asterisks as follows: *, P < 0.05 compared to vector control; **, P < 0.05 compared to
shNORE1A (One-way ANOVA followed by Student’s t-test).
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NORE1A depletion suppresses Her2+ senescence.
Activated Her2/Ras signaling has been shown to promote the phenotype of
senescence (as measured by enhanced SA-β-gal activity and p21 expression) in MCF10A cells [62]. NORE1A is required for Ras to induce senescence [36]. Her2/Ras
signaling to BRCA1 was also shown to promote senescence via upregulation of p21 [64],
[111].
I showed in Chapter V that NORE1A acts as a communication link between Ras
and BRCA1. I was therefore curious to determine whether inactivation of NORE1A
would disrupt senescence signaling between Her2/Ras and BRCA1.
To determine whether NORE1A depletion blocks the ability of Her2 to
communicate with BRCA1 and induce senescence, I stably overexpressed a
constitutively active Her2 mutant (V659E) in my matched set of NORE1A-/BRCA1MCF-10A cells (Figure 12B). These Her2+ cells were then grown for 48 hours and
assayed for senescence induction as measured by β-galactosidase activity and p21
expression.
NORE1A inactivation suppressed the ability of Her2 to induce senescence, as
indicated by a reduction in SA-β-gal activity in Her2+/NORE1A- cells. Her2+/BRCA1cells showed a ~65% increase in SA-β-gal activity compared to Her2+ control cells, and
co-depletion of NORE1A completely suppressed the BRCA1 effect (Figure 14A).
Her2+/NORE1A-/BRCA1- cells also showed a synergistic reduction in p21 expression
(Figure 14B). Interestingly, NORE1A inactivation did not show a significant reduction in
p21 expression compared to control cells. This could be explained by differences in
NORE1A knockdown levels in our NORE1A- cells compared to NORE1A-/BRCA1- cells
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(60% knockdown and 91% knockdown, respectively). Additionally, BRCA1 inactivation
did not enhance expression of p21 compared to control cells. This was surprising, as
BRCA1 knockdown has been shown to drive senescence via upregulation of both p21
and p16 [149]. This suggests that BRCA1 inactivation is driving senescence independent
of p53-p21 signaling in our system; possibly via upregulation of p16 or Rb. Further
experiments are required to determine if this is the case.
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Figure 14: NORE1A depletion suppresses senescence in Her2+/BRCA1- cells.
(A) shBRCA1 (shB) and shNORE1A (shN) MCF-10A Her2+ cells were grown in 12-well
plates and β-galactosidase activity was quantified after 24 hours. The percent increase
over Her2+ control cells was measured. Data represent the mean ± SD of triplicate
experiments. *, P < 0.05 compared to scrambled control; **, P < 0.05 compared to
shBRCA1 (one-way ANOVA followed by Student’s t-test). (Bottom) A representative
image of senescence induction in each set of cells. (B) Double knockdown of
NORE1A/BRCA1 synergistically suppresses p21. (Bottom) Western blot analysis of p21
expression from shBRCA1/shNORE1A MCF-10A Her2+ cells. The density of the bands
was quantified using ImageJ software and relative p21 expression was quantified after
normalizing to β-actin. (Top) Relative p21 levels expressed as a bar graph. Data represent
the mean ± SD of three independent experiments. *, P < 0.05 compared to scrambled
control; **, P < 0.05 compared to shBRCA1 (one-way ANOVA followed by students ttest).
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NORE1A and BRCA1 co-depletion enhances Her2/Ras transformation.
Activation of Her2/Ras in immortalized cells promotes the phenotype of
senescence, yet these cells can still proliferate and undergo anchorage-independent
growth [61], classic indicators of malignant transformation. I showed earlier that codepletion of NORE1A and BRCA1 in MCF-10A cells had an additive effect on their
proliferation rate. I was curious to determine if this increase in proliferation corresponded
with an enhanced ability to grow in soft agar. Individual knockdown of NORE1A or
BRCA1 did not permit the anchorage-independent growth of MCF-10A cells (< 7
colonies/well). However, double knockdown of NORE1A and BRCA1 was sufficient to
transform MCF-10A cells (> 40 colonies/well) (Figure 15). This is reminiscent of the
transforming effect that the NORE1A-INT domain had on these cells (Figure 11C).
Her2 overexpression alone was sufficient to promote anchorage-independent
growth of my control MCF-10A cells (> 40 colonies/well). Furthermore, co-depletion of
NORE1A and BRCA1 synergistically enhanced colony formation in my Her2+ cells (~6fold increase over Her2+ control cells) (Figure 15).
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Figure 15: NORE1A and BRCA1 co-depletion enhances MCF-10A growth in soft
agar.
shBRCA1 (shB) and shNORE1A (shN) MCF-10A cells with and without Her2overexpression (Her2+) were plated in soft agar and grown for 2 weeks at 37C. Data
represent the mean ± SD of 3 independent experiments.
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NORE1A depletion suppresses anoikis.
In order for cells to become transformed they must be able to continue
proliferating and also avoid cell death. I showed earlier in this chapter that NORE1A and
BRCA1 loss enhances the proliferation of MCF-10A cells, and that dual inactivation of
NORE1A and BRCA1 was sufficient to promote the growth of these cells in soft agar, a
marker of malignant transformation. NORE1A has a well-studied role in apoptosis [34],
[38]. Thus, I hypothesized that NORE1A loss could be conferring apoptosis resistance to
these cells.
Epithelial cells require contact with the surrounding extracellular matrix (ECM) in
order to send and receive signals essential for their growth and survival [120]. Loss of
ECM attachment can cause cells to undergo a matrix deprivation-induced apoptosis
termed anoikis [151]. The acquisition of anoikis resistance allows cells to grow under
anchorage-independent conditions [152], and is a crucial step in Ras-mediated breast
tumorigenesis [52].
To determine whether NORE1A- MCF-10A cells were resistant to anoikis, I grew
the NORE1A-/BRCA1- MCF-10A matched set of cells in suspension culture for 48 hours
and assayed for total survival, or resistance to anoikis. Cell survival was enhanced by
~200% in NORE1A knockdown cells and ~285% in NORE1A/BRCA1 double
knockdown cells (Figure 16). Cell survival was not significantly altered by BRCA1
knockdown. Thus, the effect of NORE1A on anoikis appears to be BRCA1-independent.
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Figure 16: NORE1A depletion confers anoikis resistance.
shBRCA1 (shB) and shNORE1A (shN) MCF-10A cells were grown in suspension for 48
hours and cell viability was determined by Trypan blue exclusion assay. Percentage of
cell survival is represented as mean ± SD from 3 independent experiments. *, P < 0.05
compared to scrambled control (One-way ANOVA followed by Student’s t-test).
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3. DISCUSSION
Oncogene-induced senescence occurs as a result of cells permanently disabling
their cell cycle machinery via activation of multiple tumor suppressor signaling
pathways, such as the p53-p21 and p16-Rb pathways [140]. Both NORE1A and BRCA1
play a role in Ras-induced senescence [36], [64], and can interact with p53 to promote
p21 activation [40], [147]. Using immortalized, non-transformed MCF-10A human breast
epithelial cells, I successfully established a viable model of constitutive Her2/Ras
activation that allowed us to examine the effects of NORE1A and BRCA1 inactivation on
senescence induction by these oncogenes.
Her2-overexpression has been reported to promote the senescent phenotype
(enhanced SA-β-gal activity, upregulated p21 expression) in MCF-10A cells [62]. Upon
oncogene activation, these cells have been shown to reside in a relatively stable
intermediary state until increasing levels of stress drive them to fully senesce or
transform [62]. For example, BRCA1 loss after Her2/Ras activation triggers a DNA
damage response that promotes senescence [64], [111]. The fact that inactivation of a
tumor suppressor can trigger growth arrest may seem counter-intuitive. However, this is
actually part of a controlled suicide response initiated by cells that lose BRCA1 in order
to avoid becoming malignant in the absence of adequate DNA repair mechanisms [148],
and has been observed after loss of other tumor suppressors besides BRCA1, such as the
Von Hippel-Lindau (VHL) protein [153]. Activation of Her2/Ras facilitates BRCA1
inactivation for this purpose: as a senescence fail-safe mechanism to protect cells with
activated Her2/Ras from malignant transformation.
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I discovered that NORE1A depletion disrupted the ability of Her2 expression and
BRCA1

loss

to

induce

senescence.

This

verifies

the

existence

of

a

Her2/Ras/NORE1A/BRCA1 senescence-signaling pathway, and demonstrates that
NORE1A inactivation is essential for cell survival after BRCA1 expression is lost. Thus,
NORE1A loss allows the tumorigenic effects of Her2/Ras and BRCA1 dysregulation
(e.g. accumulation of mutations caused by enhanced proliferation in the absence of errorfree DNA repair) to manifest and provides cells with the ability to subvert apoptosis and
senescence. In effect, NORE1A appears to be monitoring the “Goldilocks” response; “too
little” BRCA1 or “too much” Her2/Ras causes death as long as NORE1A expression is
“just right”. Loss of NORE1A disables this response, facilitating transformation (Figure
17).
Tumorigenesis is a multi-stage process comprised of the accumulation of cellular,
genetic, and epigenetic alterations over time [154]. These alterations allow normal cells
to progress to malignancy by overcoming pro-senescent and pro-apoptotic signaling after
Her2/Ras activation. Since NORE1A and BRCA1 are both tumor suppressors, I
hypothesized that their complex formation could play a role in tumor suppression.
Consistent with Knudson’s two-hit hypothesis [155], inactivation of NORE1A or
BRCA1 alone was not sufficient to transform immortalized MCF-10A cells into cancer
cells in vitro, suggesting that additional oncogenic hits must be required. Interestingly,
dual inactivation of NORE1A and BRCA1 was sufficient to transform MCF-10A cells, as
I hypothesized would occur based on the transforming effects of the NORE1A-INT
domain in these cells. Her2 overexpression greatly enhanced the level of transformation
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observed in NORE1A-/BRCA1- cells. Thus, I conclude that NORE1A and BRCA1 form
a tumor suppressor complex that can protect cells from Her2/Ras transformation.
An important marker of malignant transformation is the ability of cells to grow
under anchorage-independent conditions. A crucial step in obtaining anchorageindependent growth is acquiring resistance to matrix deprivation-induced apoptosis,
which is referred to as anoikis [152]. Non-transformed MCF-10A cells undergo anoikis
when they lose matrix attachment, whereas Her2/Ras-transformed MCF-10A cells will
continue to proliferate [156][157]. This Her2/Ras-induced anoikis resistance was reported
to be due in part to activation of the Raf-ERK pathway [157], [158]. However, additional
analysis on breast carcinoma cells suggests that neither ERK nor AKT activation are
necessary for Ras inhibition of anoikis [52]. Thus, additional Ras signaling pathways are
likely involved.
I hypothesized that the pro-apoptotic Ras effector NORE1A might play a role in
Ras-mediated anoikis resistance. I discovered that depletion of NORE1A conferred
anoikis resistance to MCF-10A cells. Thus, in addition to facilitating senescence bypass
after Ras activation, NORE1A inactivation also provides cells a means to subvert
apoptotic signaling.
Under normal conditions, constitutive Her2/Ras signaling drives senescence by
triggering a DNA damage response [109], [126]; or, as a fail-safe mechanism, by
inactivating BRCA1-mediated DNA repair [64], [111]. Any Her2/Ras-positive cells that
survive the senescent response and continue to proliferate will undergo anoikis before
they can metastasize. If NORE1A is inactivated, neither these pro-senescent nor proapoptotic pathways can be initiated in response to Her2/Ras activation. Consequently,
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Ras-induced hyperproliferation is allowed to continue in the absence of proper DNA
repair mechanisms, contributing to the accumulation of cancer-causing mutations. Thus,
NORE1A inactivation facilitates Her2/Ras-driven tumor formation by allowing cells to
continually proliferate without the barriers of apoptosis or senescence. The frequency of
NORE1A inactivation in breast cancers (~40%) [65] could therefore offer an explanation
for the high incidence of Ras activation (~50%) observed in sporadic breast cancers.
In conclusion, I propose that NORE1A is part of the surveillance machinery that
monitors a “Goldilocks” response to Her2/Ras activation or BRCA1 inactivation: In the
case of “too much” oncogene (Ras) or “too little” tumor suppressor (BRCA1) expression,
NORE1A levels must be “just right” in order to prevent tumor formation (Figure 17).
Since NORE1A and BRCA1 co-localize in response to replication stress, and loss of
NORE1A appears to be altering the cellular response to BRCA1, it is possible that
NORE1A plays a role in the BRCA1-mediated response to replication stress.
Experiments examining the effect of NORE1A expression on BRCA1-mediated DNA
repair could thus reveal a physiological role for their complex formation.
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Figure 17: NORE1A monitors “Goldilocks” response to Her2/Ras/BRCA1
Earlier, I described a “Goldilocks” model for senescence whereby NORE1A monitors
senescence induction in response to constitutive activation of Her2/Ras (i.e. “too much”
oncogene) or inactivation of BRCA1 (i.e. “too little” tumor suppressor). NORE1A
expression must be “just right” to monitor senescence, as loss of NORE1A expression
disables this effect and promotes tumorigenesis.
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CHAPTER VII: NORE1A REGULATES BRCA1-MEDIATED DNA REPAIR

1. INTRODUCTION
BRCA1 maintains genomic stability via checkpoint activation and DNA repair.
Genomic instability is a hallmark of cancer development [159]. One of the main
causes of genomic instability is the accumulation of DNA damage. This can occur in
response to endogenous or exogenous stressors, or from errors in DNA replication [160],
[161]. Normal cells respond to DNA damage by coordinating the activation of checkpoint
and repair pathways [107]. If the damage persists, these cells undergo apoptosis or
senescence. Failure to properly repair damaged DNA or activate growth inhibitory
pathways can lead to tumor formation.
The tumor suppressor BRCA1 acts as a central mediator of the DNA damage
response by coordinating the formation of protein complexes involved in checkpoint
activation and DNA repair [89]. Only a fraction of total cellular BRCA1 is in each of
these complexes, allowing BRCA1 to form multiple interactions simultaneously [90].
BRCA1 and binding partners abraxas and CtIP control entry into mitosis upon DNA
damage detection by enhancing the phosphorylation of checkpoint kinase 1 (CHK1) and
transiently arresting the cell cycle at G2 [162]–[164], allowing the BRCA1, BRCA2,
PALB2 and Rad51 complex to participate in homologous recombination (HR)-mediated
DNA repair [165], [166]. BRCA1, BACH1, and TopBP1 regulate entry into S-phase, and
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also help maintain and repair stalled replication forks during DNA replication [167],
[168].

Genome instability is triggered by replication stress
The majority of genomic instability that occurs in cancer cells is a result of errors
in normal DNA replication [169]. During replication, endogenous and exogenous agents
challenge genome integrity by pausing and destabilizing the replication fork. In most
cases, the replisome maintains association with the stalled fork, and replication can
resume after the stress is removed [170]. Failure to protect or restart the replication fork
in a timely manner can cause the replisome to dissociate and the fork to collapse, leading
to the formation of DSBs [171].
In response to replication fork stalling, cells trigger a replication stress response
that promotes complex formation between BRCA1 and BACH1 helicase [172]. BACH1
binds directly to the C-terminal BRCT repeats of BRCA1, a region that is essential for its
tumor suppressor function [168]. This BRCA1/BACH1 complex can transiently inhibit
DNA synthesis and participate in error-free HR-mediated DNA repair in order to resume
progression of the stalled fork [173]. Mutations in BRCA1 or BACH1 that inhibit their
complex formation render cells unable to participate in HR-mediated repair and are
associated with an increased risk for breast cancer [118], [174]–[177].

Her2/Ras activation can trigger replication stress.
Activation of oncogenes such as Her2/Ras promotes genomic instability by
enhancing the rate of cellular proliferation [178]. This results in the depletion of
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nucleotide pools, which subsequently impedes the progression of DNA replication forks
[133]. Persistently stalled forks can collapse, leading to the formation of DSBs [178]. The
replication stress and DNA damage accumulation triggered by Her2/Ras activation drives
senescence [109], and I have shown that Her2-driven senescence requires expression of
NORE1A. Additionally, activated Her2/Ras downregulates expression of BACH1, which
dissociates BRCA1 from chromatin and inactivates BRCA1-mediated DNA repair [64].
This BRCA1 inactivation drives senescence [64], but simultaneously predisposes cells to
mutations as they become reliant on more error-prone pathways of DNA repair [179].
Thus, Her2/Ras can facilitate transformation by inactivating the BRCA1/BACH1
complex and selecting for cells that acquire secondary mutations in the absence of
BRCA1-mediated HR repair [64], [111], [129].
I showed earlier that inactivation of the Ras effector NORE1A is one way that
cells can subvert Her2/Ras-mediated growth inhibition. I observed NORE1A and BRCA1
co-localizing in nuclear foci in response to Her2/Ras induced replication stress. I
hypothesized that these nuclear foci were sites of replication fork stalling, and decided to
examine the possibility that NORE1A could be participating in the BRCA1 response to
replication stress. Currently, no role for NORE1A in DNA repair has been reported.
Here, I show that NORE1A forms a complex with BACH1 and BRCA1.
Furthermore, I discovered that co-inactivation of NORE1A and BRCA1 synergizes to
suppress DNA repair. Thus, I identify a novel role for NORE1A in the control of DNA
repair by BRCA1/BACH1. As NORE1A regulates both senescence and DNA repair, it
may play a key role in the balance between growth arrest and repair after Her2/Ras
activation.
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2. RESULTS
NORE1A plays a role in BRCA1-mediated DNA repair.
I observed earlier that NORE1A and BRCA1 co-localize in nuclear foci in
response to replication stress. I also discovered that NORE1A forms a complex with
BACH1 and BRCA1, two proteins that co-localize at stalled replication forks in order to
maintain fork integrity and repair DNA DSBs [103], [168].
BRCA1 plays a key role in DNA DSB repair [89]. Consequently, BRCA1deficient cells are highly sensitive to drugs that induce DSBs. Doxorubicin hydrochloride
(Dox) is an anthracycline that stabilizes the topoisomerase II complex during replication,
causing DNA cleavage and DSB formation [180]. I subjected cells from my MCF-10A
NORE1A-/BRCA1- matched set to Dox treatment for 24 hours and then measured their
capacity for DNA repair using the comet assay.
I observed a large increase in DNA damage (i.e. enhanced DNA tail moment) in
NORE1A- and BRCA1- cells compared to control cells after treatment with Dox (Figure
18A). Additionally, I discovered that co-depletion of NORE1A and BRCA1 synergized
to suppress DNA repair after Dox treatment. Figure 18B shows representative control and
NORE1A- comet tails after Dox treatment.
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Figure 18: Dual inactivation of NORE1A and BRCA1 synergizes to suppress DNA
repair.
(A) Matched sets of cells from my NORE1A-/BRCA1- MCF-10A system were treated
with 0.3 µg/mL doxorubicin hydrochloride (Dox) for 24 hours to induce DNA damage.
Cells were harvested and assayed for changes in DNA repair activity using a comet
assay. Data was measured as comet tail moment, and represents 100 randomly chosen
cells from two independent experiments. Results are displayed as box-and-whisker plots.
The box includes 50% of the measured values for each condition, and the bottom and top
of each box represent the 25th and 75th centiles, respectively. The inner line marks the
median. Data from the upper and lower quartiles are indicated as whiskers that are
capped at the minimum or maximum calculated values. Asterisks indicate mean values
that are significantly different, as follows: *, P < 0.05 compared to the value for Dox
treated control cells. **, P < 0.05 compared to the value for Dox treated shB cells. ***, P
< 0.05 compared to the value for Dox treated shN cells. (B) Representative comet tails
after Dox treatment.
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NORE1A forms a complex with BACH1 and BRCA1.
BACH1 is a well-studied, physiological binding partner of BRCA1 [168]. These
two proteins form a tumor suppressor complex that plays a role in checkpoint control
after replication stress and HR-mediated DNA repair after DNA damage [64], [103],
[118]. I have observed NORE1A co-localizing with BRCA1 after replication stress. Since
NORE1A can function as a nuclear scaffolding protein [36], I was curious to determine
whether NORE1A could facilitate complex formation between BRCA1 and BACH1.
I was able to detect an interaction between NORE1A and BACH1 when these
proteins were overexpressed in HEK-293T cells (Figure 19A). Furthermore, I
determined that NORE1A expression enhances complex formation between BRCA1 and
BACH1 ~1.7 fold (Figure 19B).

84

Figure 19: NORE1A scaffolds BRCA1 with BACH1 helicase.
(A) HEK-293T cells were transiently transfected with either GFP-tagged NORE1A or
Myc-tagged BACH1. Cells were lysed 24 hours after transfection and equal amounts of
protein were immunoprecipitated for GFP. The immunoprecipitate was fractionated on an
SDS-polyacrylamide gel and then immunoblotted with anti-GFP and anti-Myc
antibodies. (B) HEK-293T cells were transiently transfected with either YFP-BRCA1 or
Myc-BACH1 in the presence or absence of HA-tagged NORE1A, then lysed and
Western blotted as above with anti-GFP, anti-HA, and anti-Myc antibodies. Fold change
was calculated after normalizing to total Myc-BACH1 expression levels.
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3. DISCUSSION
In this chapter, I examined the possibility that NORE1A could be regulating the
DNA repair ability of BRCA1. I proposed this hypothesis based on my observation that
these proteins co-localize in the nucleus (at what appear to be stalled replication forks) in
response to replication stress, and that NORE1A loss can alter the cellular response to
BRCA1. I provide evidence to support this hypothesis by demonstrating that NORE1A
plays a role in DNA repair. Specifically, I show that NORE1A inactivation impairs the
ability of non-transformed human mammary epithelial cells to repair DNA DSBs, and
that dual inactivation of NORE1A and BRCA1 synergistically suppresses the DNA repair
ability of these cells.
The ability of BRCA1 to participate in homologous recombination (HR)-mediated
DNA repair in response to DSB formation is determined by its interaction with BACH1
helicase. Complex formation between BRCA1 and BACH1 is required for HR-mediated
DNA repair, and depletion of either BACH1 or BRCA1 disables HR [181]. The
BRCA1/BACH1 complex is readily detected during S-phase, specifically in response to
replication stress caused by stalled or collapsed replication forks [104]. Interestingly, I
was able to detect exogenous NORE1A in a complex with BACH1, and determined that
NORE1A enhanced complex formation between BRCA1 and BACH1. Thus, it appears
that NORE1A is scaffolding the BACH1/BRCA1 interaction. One explanation for the
decreased DNA repair capability of the NORE1A- MCF-10A cells compared to control
cells might therefore be impaired complex formation between BACH1/BRCA1.
One of the more promising therapies targeting tumor cells with BRCA1
deficiency involves inhibition of poly-ADP ribose polymerase (PARP), a key enzyme
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involved in SSB DNA repair. PARP inhibitors are reported to be particularly effective
against BRCA1-null cancers, since these tumor cells are unable to use HR-mediated DSB
repair pathways and rely solely on PARP for DNA repair [182], [183]. When PARP is
also inhibited in these cells they cannot repair any DNA damage and are forced to
undergo apoptosis [184]. Unfortunately, clinical trials with PARP inhibitors have been
less than promising in treating patients with BRCA1-mutated breast cancers [185].
Interestingly, it has been shown preclinically that disruption of proteins that
interact with BRCA1 can increase PARP inhibitor sensitivity [186], [187]. Since dual
inactivation of BRCA1 and NORE1A synergize to suppress DNA repair, it is exciting to
speculate that NORE1A loss might render cells more susceptible to PARP inhibitor
treatment. Preliminary experiments in our lab showed no significant differences in
survival between my MCF-10A knockdown set of cells after treatment with the PARP
inhibitor Olaparib (data not shown). This could be due to the concentration of drug that I
chose or its efficacy in general. More recently, the PARP inhibitor Veliparib showed
promise in early clinical studies when used to treat BRCA1- sporadic breast cancers in
combination with platinum agents [188]. Thus, further experiments are required to
determine whether NORE1A-/BRCA1- cells (and breast cancers) would be more sensitive
to treatment with PARP inhibitors, alone or in tandem with other drugs like cisplatin.
In addition to its role in DNA repair, BRCA1 also has an important biological
function as an E3 ubiquitin ligase. This sole identified enzymatic activity of BRCA1
occurs within its N-terminal RING domain, and is largely enhanced by formation of a
heterodimer between BRCA1 and the BRCA1-associated RING domain protein
(BARD1) [189]. Putative targets of BRCA1-BARD1 ubiquitination include histones, γ-
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tubulin, estrogen receptor alpha (ERα), CtIP, and the checkpoint kinase 1 (CHK1) coactivator claspin [93]–[95], [190]. While the most common function of polyubiquitin
chains are to serve as a signal for proteolysis by the proteasome, it appears that BRCA1
ubiquitination does not always signal degradation of its substrates [90]. In addition, this
function of BRCA1 was shown to be disposable for its tumor suppressor function [96].
Thus, the biological consequences of BRCA1-mediated ubiquitination remain poorly
understood. Recently, NORE1A was shown to scaffold the ubiquitin ligase β-TrCP in a
Ras-regulated manner that enhances its enzymatic activity toward specific targets [83].
Given this information, it is interesting to speculate that NORE1A might also function as
a Ras-regulated scaffold for BRCA1-mediated ubiquitination of its target substrates.
Preliminary experiments in our lab have identified NORE1A as a regulator of both
Claspin and ERα ubiquitination (unpublished data). Further experiments are required to
determine whether this is a BRCA1-specific effect, as additional enzymes have been
identified that ubiquitinate these targets in vivo [191]–[193].
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CONCLUSION
Based on the results detailed in this dissertation, I propose that NORE1A and
BRCA1 form a tumor suppressor complex that either participates in DNA repair or
promotes senescence depending on the signal intensity and duration of Her2/Ras
activation. Essentially, the NORE1A/BRCA1 complex functions to regulate the balance
between growth arrest and repair after Her2/Ras activation (Figure 20).
If Her2/Ras signaling persists and excessive DNA damage accumulates, cells will
initiate a controlled suicidal response that involves the inactivation of BRCA1 [64],
[111]. NORE1A is required for this senescence induced by Her2 (shown here) and Ras
[36]. When NORE1A is not present in cells, they cannot undergo this “suicidal”
senescence triggered by constitutive Her2/Ras activation or BRCA1 inactivation and will
instead continue to grow and transform. Thus, NORE1A appears to be a key part of the
surveillance machinery that promotes a “Goldilocks” response. Too much oncogene
activation or too little tumor suppressor expression can cause cell death. Loss of
NORE1A disables this effect, allowing the tumorigenic effects of Her2 and BRCA1
dysregulation to manifest.
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Figure 20: NORE1A regulates the BRCA1 response to Ras-induced DNA damage
In response to Ras activation, NORE1A can form a complex with BRCA1 to repair
damaged DNA. If the damage is too great, NORE1A and BRCA1 can promote the
activation of p21 to drive senescence. NORE1A inactivation uncouples both Her2/Ras
and BRCA1 from senescence and impairs BRCA1-mediated DNA repair, thereby
facilitating senescence bypass and transformation.
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